Moderate- to Vigorous-Intensity Physical Activity Cuts Diabetes Risk
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, June 22, 2023 -- Physical activity is important for type 2 diabetes prevention, particularly for those with a high genetic risk, according to a study published online June 5 in the British Journal of Sports Medicine.
Mengyun Luo, from the University of Sydney, and colleagues used accelerometry data from 59,325 participants in the U.K. Biobank to examine the prospective dose-response relationships between total and intensity-specific physical activity and incident type 2 diabetes when accounting for and stratified by different levels of genetic risk.
The researchers found that during a median follow-up of 6.8 years, there was a strong linear, dose-response association between moderate- to vigorous-intensity physical activity (MVPA) and incident type 2 diabetes, even after adjusting for genetic risk. Risk declined for higher levels of MVPA (hazard ratios: 0.63 for 5.3 to 25.9 minutes/day; 0.41 for 26.0 to 68.4 minutes/day; 0.26 for >68.4 minutes/day), compared with the least active participants. There was a significant additive interaction observed between MVPA and genetic risk score, suggesting those with higher genetic risk have larger absolute risk differences by MVPA levels.
"These findings can inform future guidelines development and interventions to prevent type 2 diabetes," the authors write. "Physical activity, specifically MVPA, is beneficial, especially in those with high genetic risk, and should be promoted as a priority strategy for type 2 diabetes prevention."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.